ASCO 2026: Preview: Late-Breaking Abstracts Set to Transform the Lung Cancer Treatment Landscape
- Home
- asco conference 2026
- asco 2026 lung cancer preview
ASCO 2026 Lung Cancer Preview
ASCO 2026: Preview: Late-Breaking Abstracts Set to Transform the Lung Cancer Treatment Landscape
As the 2026 ASCO Annual Meeting approaches, the spotlight is firmly on lung cancer as several highly anticipated datasets are expected to shape future treatment strategies in both NSCLC and SCLC. The meeting is set to showcase important advancements in targeted therapies, immunotherapies, and emerging cell-based approaches across early and advanced disease settings. In addition to efficacy outcomes, ASCO 2026 is expected to emphasize long-term clinical benefit, optimal sequencing approaches, CNS activity, precision medicine strategies, and the evolving role of novel agents in frontline treatment, reflecting the continued transformation of the lung cancer treatment landscape.
Upcoming ASCO 2026 presentations are expected to showcase several potentially practice-changing targeted therapy datasets across biomarker-defined NSCLC populations. A major focus will remain on oncogene-driven disease, with emerging data evaluating next-generation EGFR, ALK, and RET-targeted therapies across both advanced and early-stage settings.
Key Targeted Therapy Insights at ASCO 2026
-
Dizal Pharmaceutical (LBA8500) will present the primary analysis from the Phase III (WU-KONG28) study evaluating sunvozertinib monotherapy versus chemotherapy in the first-line treatment of EGFR exon20ins NSCLC.
-
RET fusion-positive disease will gain significant attention through the LIBRETTO-432 trial (LBA3), which may strengthen the role of adjuvant targeted therapy. Selpercatinib following curative surgery in early-stage RET fusion-positive lung adenocarcinoma has the potential to become a new standard treatment approach.
-
Sichuan Kelun-Biotech (8506) is set to present results from the Phase III (OptiTROP-Lung05) trial assessing sac-TMT, a Trop-2 ADC, in combination with pembrolizumab versus pembrolizumab alone in first-line PD-L1–positive NSCLC.
-
Oncogene-driven NSCLC will remain a key focus at ASCO 2026, particularly with the Phase III WU-KONG28 trial evaluating sunvozertinib (Zegfrovy) versus platinum-based chemotherapy in EGFR exon 20 insertion–positive NSCLC.
-
Nuvalent (8503) will present efficacy and safety findings from the ALKOVE-1 trial evaluating neladalkib in patients with advanced ALK-positive NSCLC.
|
Abstract # |
Session Type |
Company |
Drug Name |
Indication |
Phase |
Key Focus/ Known Data | |
|
LBA3 |
Plenary Session |
|
Selpercatinib |
Stage IB-IIIA RET fusion–positive NSCLC |
Phase III (LIBRETTO-432) trial |
The presentation also reflects the broader momentum toward bringing precision medicine into earlier-stage lung cancer settings to reduce recurrence risk and improve long-term survival. | |
|
LBA4 |
Plenary Session |
|
Ivonescimab + Chemotherapy |
1L untreated advanced Squamous NSCLC |
Phase III (HARMONi-6) |
Interim OS results from HARMONi-6. Results may provide insight into whether novel combination approaches can further improve outcomes for patients with metastatic squamous NSCLC. | |
|
8000 |
Oral Abstract Session |
|
Nivolumab |
Stage IB to IIIA NSCLC |
Phase III (ECOG-ACRIN EA5142, ALCHEMIST) |
Adjuvant immunotherapy will remain a major discussion point with results from the ECOG-ACRIN EA5142 ALCHEMIST study (NCT02595944) | |
|
8006 |
Oral Abstract Session |
|
Tarlatamab |
2L treatment for SCLC |
Phase III (DeLLphi-304) |
Phase III post hoc analysis | |
|
8502 |
Oral Abstract Session |
|
Lorlatinib |
1L therapy in advanced ALK-positive NSCLC. |
Phase III (CROWN Study) |
7-year update from the Phase III study | |
|
8503 |
Oral Abstract Session |
|
Neladalkib |
ALK+ NSCLC |
Phase I/II (ALKOVE-1) |
Efficacy and safety of neladalkib | |
|
8506 |
Oral Abstract Session |
|
Sac-TMT + pembrolizumab |
1L PD-L1 positive NSCLC |
Phase III data (OptiTROP-Lung05) |
Results from the randomized Phase III data | |
|
8515 |
Rapid Oral Abstract Session |
|
Tremelimumab + durvalumab + chemotherapy |
1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) |
Phase IIb (TRITON) study |
Interim analysis of the phase 2b study.The interim analysis could help clarify whether dual checkpoint blockade strategies offer meaningful advantages in this difficult-to-treat population. | |
|
8012 |
Rapid Oral Abstract Session |
|
LB2102 |
R/R SCLC |
Phase I study |
Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy | |
|
LBA8500 |
Oral Abstract Session |
|
Sunvozertinib monotherapy |
1L EGFR exon20ins NSCLC |
Phase III (WU-KONG28 study) |
Primary analysis of a multinational Phase III randomized study | |
|
LBA8005 |
Oral Abstract Session |
|
Durvalumab |
ES-SCLC |
Phase III (TRIPLEX) trial |
Concurrent thoracic radiotherapy, platinum/etoposide chemotherapy, and durvalumab immunotherapy | |
|
LBA2007 |
Oral Abstract Session |
|
Asandeuteritnib (TY-9591) |
IL EGFR-mutated NSCLC |
Phase II (ESAONA) |
Interim analysis of an open-label, multicenter, randomized, pivotal Phase II study | |
Data Presentations Expected to Drive Attention at ASCO 2026
-
MARIPOSA remains one of the most anticipated frontline EGFR studies, evaluating amivantamab plus lazertinib versus osimertinib. With previously reported OS and PFS benefits, ASCO 2026 is expected to determine whether the combination’s maturing survival advantage is strong enough to outweigh its added treatment complexity.
-
The NeoADAURA update is also expected to attract major attention, evaluating neoadjuvant osimertinib with or without chemotherapy in resectable EGFR-mutant NSCLC. Following encouraging major pathologic response data in 2025, updated event-free survival results are anticipated with longer follow-up.
Executive Summary
As the 2026 ASCO Annual Meeting approaches, the spotlight is firmly on lung cancer as several highly anticipated datasets are expected to shape future treatment strategies in both NSCLC and SCLC.